Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466550 | 0.93 | KDM4E (0.32) | — | |
| SCHEMBL929207 | 0.93 | CHKA (0.31) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL11301415 | 0.91 | CHKA (0.30) | CHRNB2CHRNA4 | |
| SCHEMBL7877977 | 0.91 | — | — | |
| SCHEMBL20550342 | 0.91 | — | — | |
| SCHEMBL2819147 | 0.76 | — | — | |
| SCHEMBL15364407 | 0.72 | CHRNB2 (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL6406381 | 0.71 | CHRNB2 (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL8374849 | 0.67 | MAPT (0.38) | — | |
| SCHEMBL436647 | 0.65 | CHRNB2 (0.33) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099510-A1 | RESILIENT MARKER COMPOUNDS | MINTON, TREHARNE & DAVIES LIMITED (GB) | 2026-05-15 | — | — | WO | claimed |
| WO-2023139444-A1 | LIGHT-EMITTING DEVICE | 株式会社半導体エネルギー研究所 | 2023-07-27 | — | — | WO | claimed |
| US-20230200104-A1 | LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, AND METHOD FOR MANUFACTURING THE LIGHT-EMITTING ELEMENT | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2023-06-22 | — | — | US | claimed |
| WO-2026099510-A1 | RESILIENT MARKER COMPOUNDS | MINTON, TREHARNE & DAVIES LIMITED (GB) | 2026-05-15 | — | — | WO | disclosed |
| US-12604650-B2 | Method for manufacturing light-emitting element and light-emitting device using photolithography technique | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-20250089559-A1 | LIGHT-EMITTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-03-13 | — | — | US | disclosed |
| US-20240206217-A1 | Light-Emitting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-06-20 | — | — | US | disclosed |
| CN-118119203-A | Light emitting device | 株式会社半导体能源研究所 | 2024-05-31 | — | — | CN | disclosed |
| US-20230406808-A1 | DEHYDRATION OF LACTIC ACID AND RELATED COMPOUNDS IN SOLID ACIDS VIA MULTIFUNCTIONAL FLEXIBLE MODIFIERS | NATIONAL SCIENCE FOUNDATION | 2023-12-21 | — | — | US | disclosed |
| WO-2023139444-A1 | LIGHT-EMITTING DEVICE | 株式会社半導体エネルギー研究所 | 2023-07-27 | — | — | WO | disclosed |
| US-20230200198-A1 | LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, AND METHOD FOR MANUFACTURING THE LIGHT-EMITTING ELEMENT | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230200104-A1 | LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, AND METHOD FOR MANUFACTURING THE LIGHT-EMITTING ELEMENT | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | CHRNB2 4666/4885CHRNA4 4792/4885 |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | CHRNB2 4674/4885CHRNA4 4557/4885 |
| US-12604650-B2 | Method for manufacturing light-emitting element and light-emitting device using photolithography technique | ASIC1, ASIC3, CA1 | CHRNB2 677/4885CHRNA4 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.